Recent Posts
Deals•Feb 2, 2026
Wave Life Sciences Reacquires Global Rights to RNA Editing Drug WVE-006 From GSK
Wave Life Sciences announced it has reached a deal with GSK to reclaim global rights to its RNA editing therapy WVE-006 for alpha‑1 antitrypsin deficiency, ending GSK’s involvement in the program. The rights transfer follows a 2022 collaboration and is part of a broader agreement that could see Wave receive up to $2.8 billion. The deal was disclosed on Feb 2 2026.
BioPharma Dive
News•Jan 30, 2026
Amgen Gives up on Its Once-Prized Eczema Drug
Amgen has terminated its collaboration with Kyowa Kirin on the OX40‑targeting eczema drug rocatinlimab, returning all rights to the Japanese partner. The decision follows Phase 3 trials that met primary endpoints but failed to demonstrate superiority over established therapy Dupixent and showed...
By BioPharma Dive
News•Jan 30, 2026
Politicization Runs Deeper than Ever at FDA, Risking Long-Term Impacts
The FDA has undergone an unprecedented wave of politicization in the past year, marked by mass staff departures, early retirements, and a surge of political appointees across senior roles. This shift has altered advisory committees, review processes, and introduced the...
By BioPharma Dive
Deals•Jan 28, 2026
Halozyme Therapeutics Acquires Surf Bio for up to $400M
Halozyme Therapeutics announced the acquisition of privately held drug delivery specialist Surf Bio. The deal includes an upfront payment of $300 million with potential earn‑out bringing total consideration to $400 million. The acquisition aims to expand Halozyme’s platform for high‑concentration...
BioPharma Dive
News•Jan 26, 2026
Express Scripts Considering Settlement in FTC Insulin Price Lawsuit
Cigna’s pharmacy‑benefit manager Express Scripts is reportedly close to a settlement with the Federal Trade Commission over allegations that the PBM helped inflate insulin prices. The FTC has paused the broader case to allow settlement talks with Express Scripts, CVS...
By BioPharma Dive
News•Jan 26, 2026
The Crucial Role of Raw Material Selection for Success in Cell Therapy Manufacturing
Cell therapy’s promise hinges on manufacturing consistency, which is driven by the quality of raw (ancillary) materials such as media, cytokines, scaffolds, and disposables. Variability in these inputs can cause fluctuations in cell potency, safety, and regulatory compliance, especially when...
By BioPharma Dive
News•Jan 26, 2026
From Detection to Prevention: How Sponsored Testing Can Transform Patient Outcomes
Diagnostic testing is evolving from a purely detection tool to a preventive strategy, especially in Canada where provincial coverage varies. Pharmaceutical sponsors are launching paid testing programs that eliminate cost barriers, granting patients access to advanced risk‑identification assays for conditions...
By BioPharma Dive
Deals•Jan 26, 2026
Helix Acquisition Corp. III, Backed by Cormorant, Raises $150M in IPO
Biotech investor Cormorant Asset Management launched Helix Acquisition Corp. III, a SPAC that raised $150 million in its initial public offering on the Nasdaq. The SPAC, which currently has no merger target, aims to focus on healthcare and related industries....
BioPharma Dive
Deals•Jan 23, 2026
Terns Pharmaceuticals Secures Full Licensing Rights for Leukemia Drug TERN-701 From Hansoh Pharmaceutical
Terns Pharmaceuticals amended its licensing agreement with China's Hansoh Pharmaceutical, paying a $1 million upfront fee and a modest royalty to obtain the right to license TERN-701, its chronic myeloid leukemia candidate, in territories where Hansoh holds no rights. The...
BioPharma Dive
News•Jan 22, 2026
FDA Lays Out New Path to Speed Development of Multiple Myeloma Drugs
The FDA released new guidance allowing accelerated approval of multiple myeloma therapies based on minimal residual disease (MRD) or complete response endpoints. This shift lets sponsors use single‑arm or randomized trials focused on deep molecular responses, reducing the need for...
By BioPharma Dive
Deals•Jan 22, 2026
Mendra Therapeutics Raises $82M Series A to Accelerate Rare Disease Drug Development
Mendra Therapeutics, a new biotech founded by former BioMarin executives, announced an $82 million Series A financing led by OrbiMed, 8VC and 5AM Ventures. The capital will be used to acquire rare‑disease assets and accelerate development with AI. The funding was disclosed...
BioPharma Dive
Deals•Jan 22, 2026
Corxel Secures $287M Series D1 Funding to Advance Oral GLP-1 Obesity Pill
Corxel Pharmaceuticals announced a $287 million Series D1 financing round, with investors including SR One, TCGX, RA Capital Management, RTW Investments and Hengdian Group Capital. The capital will fund development of its oral GLP‑1 obesity drug CX11, licensed from China’s Vincentage, underscoring strong venture...
BioPharma Dive
News•Jan 21, 2026
J&J Eyes $100B in Sales Amid Gains for Cancer, Immune Drugs
Johnson & Johnson reported a 9.1% rise in fourth‑quarter sales to $24.6 billion and projected full‑year revenue of $100‑101 billion for 2026, up from $94.2 billion. The company’s growth is driven by strong cancer and immune‑therapy sales, offsetting a steep decline in its...
By BioPharma Dive
News•Jan 20, 2026
When Every Day Counts: Building CRO Partnerships on a Foundation of Trust, Care and Precision
Almac Clinical Services positions its "Supply with Care" model as a trust‑based solution for CROs facing costly clinical‑supply delays. The firm highlights a global depot network, real‑time visibility tools, and dedicated CRO operational leads to keep medicines on schedule. By...
By BioPharma Dive
News•Jan 20, 2026
The Patient Retention Crisis Is Happening Before Enrollment Even Begins
A new State of Enrollment 2026 report reveals that most patient loss happens before enrollment, with 48% dropping out during pre‑screening, 38% at phone screening, and 36% during eligibility review. This upstream attrition is invisible on traditional enrollment dashboards, shifting the...
By BioPharma Dive
News•Jan 15, 2026
Boston Scientific to Acquire Penumbra for $14.5B
Boston Scientific announced a $14.5 billion acquisition of Penumbra, paying $374 per share in cash and stock. Penumbra’s portfolio of clot‑removal and embolization devices will broaden Boston Scientific’s reach into fast‑growing thrombectomy and vascular bleeding markets. The deal values Penumbra at...
By BioPharma Dive
News•Jan 13, 2026
Digital Health Funding Increases in 2025, Spurred by AI: Report
Digital health funding jumped to $14.2 billion in 2025, the highest level since 2022, driven largely by artificial‑intelligence startups. AI‑focused firms secured 54% of total capital and enjoyed a 19% premium in average deal size versus non‑AI peers. Although the total...
By BioPharma Dive
News•Jan 13, 2026
What Sanofi’s Multiple Sclerosis Troubles Could Mean for the Space
Sanofi’s BTK inhibitor tolebrutinib failed pivotal late‑stage trials in both relapsing and primary progressive multiple sclerosis, prompting the FDA to reject its approval over liver toxicity concerns. The setback highlights the challenges of BTK‑targeted therapies, even as competitors like Roche’s...
By BioPharma Dive
News•Jan 12, 2026
5 Questions Facing Biopharma in 2026
The 2026 J.P. Morgan Healthcare Conference highlighted five critical questions for biopharma: whether the 2025 recovery will sustain, if the recent surge in M&A will continue, how the U.S. will counter China’s fast‑growing biotech sector, whether FDA leadership turmoil will...
By BioPharma Dive
News•Jan 12, 2026
Best Practices for COA Selection: Building a Stronger Foundation for Clinical Trials
Selecting the right clinical outcome assessment (COA) is now a pivotal determinant of trial success, influencing regulatory acceptance and data relevance. A Pearson Research survey shows 91% of investigators feel under‑prepared, with licensing, translation, and rater training cited as the...
By BioPharma Dive
News•Jan 12, 2026
Building More Sustainable Cold Chain Packaging Through Innovation
The pharmaceutical cold‑chain still depends on single‑use expanded polystyrene (EPS) for reliable temperature control, but that reliance generates a massive waste stream and high carbon emissions. Global EPS production exceeds 5 million metric tons annually, yet recycling rates linger below 30 percent,...
By BioPharma Dive
News•Jan 12, 2026
Eikon, a High-Profile Startup Led by Merck Vets, Seeks an IPO
Eikon Therapeutics, a biotech founded in 2019 by former Merck executives, has raised more than $1 billion and announced plans for an initial public offering. The company’s pipeline includes four clinical candidates, with its lead asset EIK1001 advancing in a Phase 2/3...
By BioPharma Dive
News•Jan 9, 2026
Aurora Sets Out to Capitalize on FDA’s New Framework for Bespoke Drug Therapies
Biotech startup Aurora Therapeutics, co‑founded by Nobel laureate Jennifer Doudna and genetic‑medicine pioneer Fyodor Urnov, announced a $16 million seed round from Menlo Ventures. The company plans to leverage the FDA’s newly introduced “plausible mechanism” regulatory pathway to fast‑track multiple CRISPR‑based...
By BioPharma Dive
Deals•Jan 9, 2026
Aurora Therapeutics Raises $16M Seed Round From Menlo Ventures
Aurora Therapeutics, a biotech startup co‑founded by Nobel laureate Jennifer Doudna and Fyodor Urnov, announced a $16 million seed round from Menlo Ventures to develop gene‑editing therapies for rare diseases under the FDA’s plausible mechanism pathway. The company will initially target...
BioPharma Dive
News•Jan 8, 2026
Diagonal Banks Another $125M for ‘Clustering’ Antibody Drugs
Biotech startup Diagonal Therapeutics secured $125 million in a Series B financing, bringing its total capital raised since 2024 to over $250 million. The funding will advance its lead candidate, DIAG723, a clustering antibody designed to reactivate the ALK1 pathway...
By BioPharma Dive
Deals•Jan 8, 2026
Parabilis Medicines Secures $305M Series F Funding Led by RA Capital, Fidelity Management, and Janus Henderson
Parabilis Medicines announced a $305 million Series F financing round, led by RA Capital Management, Fidelity Management, and Janus Henderson Investors. The capital will fund the development of its lead candidate zolucatetide, targeting the beta‑catenin pathway in cancer, and expand...
BioPharma Dive
Deals•Jan 8, 2026
EpiBiologics Raises $107M in Series B to Advance Protein-Degrading Cancer Drug
Biotech startup EpiBiologics announced a $107 million Series B financing to push its lead protein-degrading cancer therapy, EPI-326, into clinical trials. The round was co-led by GV and Johnson & Johnson’s corporate venture arm, with participation from Novartis Venture Fund,...
BioPharma Dive
News•Jan 7, 2026
Lilly Snaps up Ventyx for $1.2B in Pursuit of Oral Immune Drugs
Eli Lilly agreed to acquire Ventyx Biosciences for $1.2 billion, paying a 62 % premium to secure the oral NLRP3 inhibitor VTX3232. The drug showed a 64 % reduction in a cardiac‑risk biomarker and synergistic effects with semaglutide in obesity‑related trials. The purchase expands...
By BioPharma Dive
News•Jan 7, 2026
5 FDA Decisions to Watch in the First Quarter of 2026
Eli Lilly’s oral GLP‑1 candidate orforglipron received a national‑priority voucher, accelerating its FDA review and threatening Novo Nordisk’s recent oral Wegovy launch. Disc Medicine’s repurposed schizophrenia drug bitopertin is on the brink of approval for the rare disease erythropoietic protoporphyria,...
By BioPharma Dive
News•Jan 6, 2026
Alumis Soars as TYK2 Drug Hits Mark in Psoriasis Trials
Alumis announced that its TYK2 inhibitor envudeucitinib met primary endpoints in two Phase 3 psoriasis trials, delivering 74% of patients achieving PASI‑75 after four months. The data suggest efficacy comparable to leading oral candidates and injectable biologics, prompting the stock to...
By BioPharma Dive